Krystal Biotech Inc's stock increased by 5.03% as it crossed above the 5-day SMA, reflecting positive investor sentiment.
This rise is amid the company's participation in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, where CEO Krish S. Krishnan will present advancements in gene therapy. Additionally, an interim clinical update on KB407 from the CORAL-1 study is set to be released on January 8, 2026, which could provide significant insights into new treatment options for cystic fibrosis patients, enhancing market interest in Krystal Biotech's innovative therapies.
The combination of these events is likely to attract more investors and strengthen the company's position in the biotechnology sector, particularly with the ongoing commercialization of its gene therapy product, VYJUVEK®.
Wall Street analysts forecast KRYS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 221.00 USD with a low forecast of 198.00 USD and a high forecast of 255.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast KRYS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 221.00 USD with a low forecast of 198.00 USD and a high forecast of 255.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 248.910
Low
198.00
Averages
221.00
High
255.00
Current: 248.910
Low
198.00
Averages
221.00
High
255.00
BofA
Buy
maintain
$272 -> $288
2026-01-09
New
Reason
BofA
Price Target
$272 -> $288
2026-01-09
New
maintain
Buy
Reason
BofA raised the firm's price target on Krystal Biotech to $288 from $272 and keeps a Buy rating on the shares. Following updates from the phase 1 CORAL-1 study, the firm continues to like Krystal as one of its top picks for the year as it thinks both Vyjuvek and the pipeline could unlock "significant value," the analyst tells investors.
TD Cowen
Buy
maintain
$202 -> $306
2026-01-09
New
Reason
TD Cowen
Price Target
$202 -> $306
2026-01-09
New
maintain
Buy
Reason
TD Cowen raised the firm's price target on Krystal Biotech to $306 from $202 and keeps a Buy rating on the shares. The firm updated its model following the release of robust Ph 1/2 407 data on in CF.
TD Cowen
Buy
upgrade
$202 -> $306
2026-01-09
New
Reason
TD Cowen
Price Target
$202 -> $306
2026-01-09
New
upgrade
Buy
Reason
TD Cowen raised the firm's price target on Krystal Biotech to $306 from $202 and keeps a Buy rating on the shares. The firm updated its model following the release of "robust" Phase 1/2 data on KB407 in cystic fibrosis, the analyst tells investors.
Clear Street
Buy
upgrade
$217 -> $288
2026-01-09
New
Reason
Clear Street
Price Target
$217 -> $288
2026-01-09
New
upgrade
Buy
Reason
Clear Street raised the firm's price target on Krystal Biotech to $288 from $217 and keeps a Buy rating on the shares. The firm says KB407 successfully induced wild-type CFTR protein expression in patient lung epithelial cells, at levels that are expected to be therapeutically meaningful.
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
